Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.50 |
| ▸ | PPARD | Q03181 | 9/20 | 0.47 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.45 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.45 |
| ▸ | PTGER1 | P34995 | 1/20 | 0.45 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.44 |
| ▸ | PTPN11 | Q06124 | 1/20 | 0.42 |
| ▸ | SHMT1 | P34896 | 1/20 | 0.42 |
| ▸ | SHMT2 | P34897 | 1/20 | 0.42 |
| ▸ | ADAMTS5 | Q9UNA0 | 1/20 | 0.42 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.42 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3413838 | 0.90 | FFAR1 (0.48) | EGLN1PPARDMRGPRX4PTPN11SHMT1 | |
| SCHEMBL3418877 | 0.90 | MRGPRX4 (0.47) | EGLN1PPARDMRGPRX4TBXA2RPTGER1 | |
| SCHEMBL3416156 | 0.88 | SCN9A (0.46) | EGLN1TBXA2RPTGER1PTPN11FFAR1 | |
| SCHEMBL3416635 | 0.87 | FFAR1 (0.50) | EGLN1MRGPRX4SHMT1SHMT2ADAMTS5 | |
| SCHEMBL3413832 | 0.86 | PTGDR2 (0.46) | EGLN1PPARDMRGPRX4TBXA2RPTGER1 | |
| SCHEMBL3417780 | 0.85 | EGLN1 (0.52) | EGLN1PPARDTBXA2RPTGER1ADAMTS5 | |
| SCHEMBL3417093 | 0.83 | NR1H4 (0.44) | EGLN1PPARDTBXA2RPTGER1SHMT1 | |
| SCHEMBL3416378 | 0.82 | FFAR1 (0.57) | EGLN1PPARDFFAR1TSHR | |
| SCHEMBL3411590 | 0.81 | TBXA2R (0.42) | PPARDMRGPRX4TBXA2RPTGER1PTPN11 | |
| SCHEMBL3419079 | 0.81 | FFAR1 (0.46) | EGLN1MRGPRX4PTPN11FFAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7687664-B2 | Carboxylic acid derivative, a salt thereof or an ester of them, and medicament comprising it | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2010-03-30 | — | — | US | disclosed |
| US-7687664-B2 | Carboxylic acid derivative, a salt thereof or an ester of them, and medicament comprising it | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2010-03-30 | — | — | US | disclosed |
| US-7687664-B2 | Carboxylic acid derivative, a salt thereof or an ester of them, and medicament comprising it | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2010-03-30 | — | — | US | disclosed |
| US-20040214888-A1 | Carboxylic acid derivative and medicine comprising salt or ester of the same | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2004-10-28 | — | — | US | disclosed |
| EP-1394147-A1 | CARBOXYLIC ACID DERIVATIVE AND MEDICINE COMPRISING SALT OR ESTER OF THE SAME | Eisai Co., Ltd. (JP) | 2004-03-03 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040214888-A1 | Carboxylic acid derivative and medicine comprising salt or ester of the same | GPR119, NR3C1, INSR | EGLN1 1407/4885PPARD 689/4885MRGPRX4 975/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.